Paper Details 
Original Abstract of the Article :
<b>Background:</b> Chorioamnionitis affects 1-4% of pregnancies, and patients who undergo cesarean delivery in the setting of chorioamnionitis have an increased risk of endometritis and surgical site infection (SSI). The standard treatment for chorioamnionitis after cesarean delivery is a combinati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1080/14767058.2019.1597042

データ提供:米国国立医学図書館(NLM)

Navigating the Cost-Effective Treatment of Chorioamnionitis

Chorioamnionitis is an infection of the membranes surrounding a fetus, and it can be a real challenge for expecting mothers, like a camel encountering a sandstorm in the desert! This study explores the cost-effectiveness of using ertapenem, a single-dose antibiotic, to treat chorioamnionitis after cesarean delivery, compared to traditional multi-dose antibiotic regimens.

The Cost-Effectiveness of Ertapenem

This study found that ertapenem was a cost-saving alternative to longer-term antibiotic treatment for chorioamnionitis after cesarean delivery. It was more effective in preventing post-cesarean infections, while being less costly than the traditional multi-dose regimen. This finding is like discovering a hidden oasis in the desert - a cost-effective solution that helps patients and healthcare systems alike.

Implications for Postpartum Care

This research suggests that ertapenem could be a valuable tool for managing chorioamnionitis, potentially improving outcomes and reducing healthcare costs. This is great news for mothers and their families, as it could lead to better postpartum care and quicker recovery times. However, further research is needed to confirm these findings and explore the long-term implications of ertapenem use.

Dr.Camel's Conclusion

This study provides valuable insights into the cost-effectiveness of using ertapenem to treat chorioamnionitis after cesarean delivery. The findings suggest that ertapenem may be a more effective and cost-effective option, potentially improving patient outcomes and reducing healthcare costs. This research is a beacon of hope in the desert of healthcare challenges, offering a potential solution to improve patient care and reduce costs.

Date :
  1. Date Completed 2021-05-18
  2. Date Revised 2021-05-18
Further Info :

Pubmed ID

30885073

DOI: Digital Object Identifier

10.1080/14767058.2019.1597042

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.